Bandingkan Harga & Kinerja Organon Pharma Indonesia Tbk. (SCPI) vs Reksa Dana Danareksa ETF Indonesia Top 40 (XDIF)

Organon Pharma Indonesia Tbk.Trading

Reksa Dana Danareksa ETF Indonesia Top 40Trading

Kinerja harga (24 Jam Terakhir)

Statistik utama

Perbedaan Organon Pharma Indonesia Tbk. dan Reksa Dana Danareksa ETF Indonesia Top 40: Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M), sedangkan Reksa Dana Danareksa ETF Indonesia Top 40 diperdagangkan di Rp438 (kapitalisasi pasar 31,71 M). Perbedaan utamanya: Organon Pharma Indonesia Tbk. jauh lebih besar — sekitar 3,3× kapitalisasi pasar Reksa Dana Danareksa ETF Indonesia Top 40. Mana yang lebih baik tergantung tujuan investasimu.

	SCPI	XDIF
Kapitalisasi Pasar	104,4 M	31,71 M

Lihat detail →Lihat detail →

Perbandingan imbal hasil

Imbal hasil berjalan pada periode standar

Berita terkini

Berita terbaru kedua aset

SCPI

Lihat detail →

XDIF

Lihat detail →

Tentang Organon Pharma Indonesia Tbk.

PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.

Selengkapnya di halaman SCPI →